Citation Report
List of articles citing

Restoration of cone vision in a mouse model of achromatopsi

DOI: 10.1038/nm1596
Nature Medicine, 2007, 13, 685-7.

Source: https://exaly.com/paper-pdf/42810134/citation-report.pdf
Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
193	A mutation in the cone-specific pde6 gene causes rapid cone photoreceptor degeneration in zebrafish. **2007**, 27, 13866-74		86
192	Cyclops. **2007**, 42, 523		
191	Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. *Gene Therapy*, **2008**, 15, 1049-55	4	47
190	AAV-mediated gene therapy for retinal disorders: from mouse to man. *Gene Therapy*, **2008**, 15, 849-57	4	94
189	Comparative analysis of in vivo and in vitro AAV vector transduction in the neonatal mouse retina: effects of serotype and site of administration. **2008**, 48, 377-85		66
188	In vivo imaging of the photoreceptor mosaic of a rod monochromat. **2008**, 48, 2564-8		67
187	Enhanced transduction and improved photoreceptor survival of retinal degeneration by the combinatorial use of rAAV2 with a lower dose of adenovirus. **2008**, 48, 1648-54		12
186	The role of cis-regulatory elements in the design of gene therapy vectors for inherited blindness. *Expert Opinion on Biological Therapy*, **2008**, 8, 599-608	5.4	3
185	Longitudinal evaluation of expression of virally delivered transgenes in gerbil cone photoreceptors. **2008**, 25, 273-82		6
184	AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. **2008**, 49, 4278-83		108
183	[The treatment of inherited dystrophies and neovascular disorders of the retina by rAAV-mediated gene therapy]. **2008**, 225, 1009-23		3
182	Inherited diseases of photoreceptors and prospects for gene therapy. **2008**, 9, 335-47		5
181	Monitoring mouse retinal degeneration with high-resolution spectral-domain optical coherence tomography. **2008**, 8, 17.1-11		58
180	Functional interchangeability of rod and cone transducin alpha-subunits. **2009**, 106, 17681-6		34
179	Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism. **2009**, 18, 4770-80		62
178	Rod and rod-driven function in achromatopsia and blue cone monochromatism. **2009**, 50, 950-8		37
177	Prospects for retinal gene replacement therapy. **2009**, 25, 156-65		65

176	Naturally occurring animal models with outer retina phenotypes. **2009**, 49, 2636-52		69
175	The use of canine models of inherited retinal degeneration to test novel therapeutic approaches. **2009**, 12, 192-204		33
174	Ocular gene therapy: current progress and future prospects. **2009**, 15, 23-31		58
173	A novel day blindness in sheep: epidemiological, behavioural, electrophysiological and histopathological studies. **2010**, 185, 130-7		27
172	Day blind sheep and the importance of large animal disease models. **2010**, 185, 241-2		5
171	Colour vision deficiency. **2010**, 24, 747-55		87
170	Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. *Gene Therapy*, **2010**, 17, 117-31	4	103
169	Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. *Gene Therapy*, **2010**, 17, 815-26	4	60
168	Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. *PLoS ONE*, **2010**, 5, e9200	3.7	97
167	Color vision defects. **2010**, 478-485		
166	Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. *Journal of Clinical Investigation*, **2010**, 120, 3042-53	15.9	155
165	Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. **2010**, 51, 5952-7		127
164	Mutation discovered in a feline model of human congenital retinal blinding disease. **2010**, 51, 2852-9		47
163	Mechanistic basis for the failure of cone transducin to translocate: why cones are never blinded by light. **2010**, 30, 6815-24		50
162	Gene therapy rescues cone function in congenital achromatopsia. **2010**, 19, 2581-93		203
161	Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. **2010**, 71, 97-102		27
160	Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. *Molecular Therapy*, **2010**, 18, 2057-63	11.7	149
159	Retinal Diseases. **2010**, 327-344		

158	Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. **2010**, 90, 546-54		41
157	Retinal Degenerative Diseases. *Advances in Experimental Medicine and Biology*, **2010**,	3.6	16
156	Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. *Human Gene Therapy*, **2011**, 22, 1179-90	4.8	65
155	Photoreceptor structure and function in patients with congenital achromatopsia. **2011**, 52, 7298-308		123
154	Adeno-Associated Virus. *Methods in Molecular Biology*, **2011**,	1.4	10
153	Republished review: Gene therapy for ocular diseases. **2011**, 87, 487-95		11
152	Gene therapy for ocular diseases. *British Journal of Ophthalmology*, **2011**, 95, 604-12	5.5	54
151	High-resolution in vivo imaging in achromatopsia. *Ophthalmology*, **2011**, 118, 882-7	7.3	96
150	Distinct and conserved prominin-1/CD133-positive retinal cell populations identified across species. *PLoS ONE*, **2011**, 6, e17590	3.7	20
149	AAV-mediated photoreceptor transduction of the pig cone-enriched retina. *Gene Therapy*, **2011**, 18, 637-45		69
148	Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identification of a new nonsense mutation in GNAT2 gene. **2011**, 56, 22-8		15
147	Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. **2011**, 20, 3161-75		137
146	C1q enhances cone photoreceptor survival in a mouse model of autosomal recessive retinitis pigmentosa. **2012**, 20, 64-8		13
145	The effect of cone opsin mutations on retinal structure and the integrity of the photoreceptor mosaic. **2012**, 53, 8006-15		69
144	AAV-mediated gene therapy in mouse models of recessive retinal degeneration. **2012**, 12, 316-30		11
143	Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. **2012**, 109, 2132-7		203
142	Gene delivery to the retina: from mouse to man. **2012**, 507, 255-74		12
141	Optical coherence tomography studies provides new insights into diagnosis and prognosis of infantile nystagmus: a review. **2012**, 20, 175-80		12

140	Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro. **2012**, 97, 148-53		3
139	Gene supplementation therapy for recessive forms of inherited retinal dystrophies. *Gene Therapy*, **2012**, 19, 154-61	4	43
138	Novel adeno-associated viral vectors for retinal gene therapy. *Gene Therapy*, **2012**, 19, 162-8	4	97
137	The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. *Human Gene Therapy*, **2012**, 23, 1101-15	4.8	88
136	Adeno-associated virus mediated gene therapy for retinal degenerative diseases. *Methods in Molecular Biology*, **2011**, 807, 179-218	1.4	25
135	Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. *Human Gene Therapy*, **2012**, 23, 796-807	4.8	37
134	Secretase inhibition of murine choroidal neovascularization is associated with reduction of superoxide and proinflammatory cytokines. **2012**, 53, 574-85		11
133	Gene therapy in age related macular degeneration and hereditary macular disorders. **2012**, 4, 2546-57		7
132	Restoration of vision after transplantation of photoreceptors. **2012**, 485, 99-103		364
131	Retinal dystrophies and gene therapy. **2012**, 171, 757-65		19
130	X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. **2012**, 31, 195-212		187
129	Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction. **2012**, 428, 58-63		8
128	Retinal Degeneration. *Methods in Molecular Biology*, **2013**,	1.4	10
127	Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. **2013**, 14, 27		22
126	Color Vision Defects. **2013**, 1-17		1
125	Physiology and pathology of saccades and gaze holding. **2013**, 32, 493-505		7
124	Adaptive optics retinal imaging--clinical opportunities and challenges. **2013**, 38, 709-21		57
123	Abnormalities of Cone and Rod Function. **2013**, 899-906		2

122	A comprehensive review of retinal gene therapy. *Molecular Therapy*, **2013**, 21, 509-19	11.7	208
121	Gene therapy for retinal disease. **2013**, 161, 241-54		54
120	Clinical applications of retinal gene therapy. **2013**, 32, 22-47		89
119	Gene therapy for blindness. **2013**, 36, 467-88		101
118	Gene Therapy for Retinal Disease. **2013**, 652-668		2
117	Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. *Molecular Therapy*, **2013**, 21, 1131-41	11.7	60
116	Is high-resolution spectral domain optical coherence tomography reliable in nystagmus?. *British Journal of Ophthalmology*, **2013**, 97, 534-6	5.5	10
115	Loss of scotopic contrast sensitivity in the optomotor response of diabetic mice. **2013**, 54, 1536-43		14
114	CRB1: one gene, many phenotypes. **2013**, 28, 397-405		25
113	AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. *Human Gene Therapy*, **2013**, 24, 189-202	4.8	51
112	A naturally occurring mouse model of achromatopsia: characterization of the mutation in cone transducin and subsequent retinal phenotype. **2013**, 54, 3350-9		28
111	Survey of common eye diseases in laboratory mouse strains. **2013**, 54, 4974-81		68
110	Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy. *PLoS ONE*, **2014**, 9, e92928	3.7	19
109	Insights gained from gene therapy in animal models of retGC1 deficiency. **2014**, 7, 43		10
108	Genotype-dependent variability in residual cone structure in achromatopsia: toward developing metrics for assessing cone health. **2014**, 55, 7303-11		56
107	Dark-adaptation functions in molecularly confirmed achromatopsia and the implications for assessment in retinal therapy trials. **2014**, 55, 6340-9		11
106	Gene therapies for inherited retinal disorders. **2014**, 31, 289-307		10
105	[Gene replacement therapy in achromatopsia type 2]. **2014**, 231, 232-40		2

104	A prospective longitudinal study of retinal structure and function in achromatopsia. **2014**, 55, 5733-43		55
103	Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy. **2014**, 132, 823-31		28
102	In vivo imaging of human cone photoreceptor inner segments. **2014**, 55, 4244-51		236
101	TCongenitalTnystagmus may hide various ophthalmic diagnoses. **2014**, 92, 412-6		8
100	Achromatopsia: case presentation and literature review emphasising the value of spectral domain optical coherence tomography. **2014**, 97, 507-10		6
99	Retinal structure and function in achromatopsia: implications for gene therapy. *Ophthalmology*, **2014**, 121, 234-245	7.3	119
98	Migration, integration and maturation of photoreceptor precursors following transplantation in the mouse retina. **2014**, 23, 941-54		53
97	Retinal gene therapy using adeno-associated viral vectors: multiple applications for a small virus. *Human Gene Therapy*, **2014**, 25, 671-8	4.8	7
96	Vector platforms for gene therapy of inherited retinopathies. **2014**, 43, 108-28		106
95	Expression of a single prominin homolog in the embryo of the model chordate Ciona intestinalis. **2014**, 15, 38-45		4
94	Causes and consequences of inherited cone disorders. **2014**, 42, 1-26		102
93	Organization of the Central Visual Pathways Following Field Defects Arising from Congenital, Inherited, and Acquired Eye Disease. *Annual Review of Vision Science*, **2015**, 1, 329-350	8.2	6
92	Achromatopsia: a review. *Current Opinion in Ophthalmology*, **2015**, 26, 333-40	5.1	51
91	Canine CNGA3 Gene Mutations Provide Novel Insights into Human Achromatopsia-Associated Channelopathies and Treatment. *PLoS ONE*, **2015**, 10, e0138943	3.7	15
90	Assessment of Visual and Chromatic Functions in a Rodent Model of Retinal Degeneration. **2015**, 56, 6275-83		7
89	Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia. *Nature Genetics*, **2015**, 47, 757-65	36.3	143
88	The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. *Cold Spring Harbor Perspectives in Medicine*, **2015**, 5, a017285	5.4	110
87	Genetics and Disease Expression in the CNGA3 Form of Achromatopsia: Steps on the Path to Gene Therapy. *Ophthalmology*, **2015**, 122, 997-1007	7.3	49

86	Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 95, 343-52	5.7	51
85	Gene Therapy for Blinding Pediatric Eye Disorders. *Advances in Pediatrics*, **2015**, 62, 185-210	2.2	2
84	Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia. *Molecular Therapy*, **2015**, 23, 1423-33	11.7	75
83	Biology and therapy of inherited retinal degenerative disease: insights from mouse models. *DMM Disease Models and Mechanisms*, **2015**, 8, 109-29	4.1	160
82	Leber congenital amaurosis caused by mutations in GUCY2D. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 5, a017350	5.4	17
81	Retinal Remodeling: Concerns, Emerging Remedies and Future Prospects. *Frontiers in Cellular Neuroscience*, **2016**, 10, 38	6.1	14
80	The Genetics of Color Vision and Congenital Color Deficiencies. **2016**, 1-32		2
79	Basic FGF or VEGF gene therapy corrects insufficiency in the intrinsic healing capacity of tendons. *Scientific Reports*, **2016**, 6, 20643	4.9	44
78	Mouse Models of NMNAT1-Leber Congenital Amaurosis (LCA9) Recapitulate Key Features of the Human Disease. *American Journal of Pathology*, **2016**, 186, 1925-1938	5.8	28
77	Advances in Gene Therapy for Diseases of the Eye. *Human Gene Therapy*, **2016**, 27, 563-79	4.8	54
76	Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases. *Human Gene Therapy*, **2016**, 27, 72-82	4.8	46
75	Gene and cell-based therapies for inherited retinal disorders: An update. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2016**, 172, 349-366	3.1	50
74	Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa. *Gene Therapy*, **2016**, 23, 196-204	4	50
73	The cone dysfunction syndromes. *British Journal of Ophthalmology*, **2016**, 100, 115-21	5.5	91
72	Gene therapy for achromatopsia. *Journal of Gene Medicine*, **2017**, 19, e2944	3.5	29
71	Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. *Molecular Therapy*, **2017**, 25, 1076-1094	11.7	67
70	Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. **2017**,		0
69	Vectors and Gene Delivery to the Retina. *Annual Review of Vision Science*, **2017**, 3, 121-140	8.2	29

68	AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term Effects. *Frontiers in Neuroscience*, **2017**, 11, 292	5.1	18
67	The Degeneration and Apoptosis Patterns of Cone Photoreceptors in Mice. *Journal of Ophthalmology*, **2017**, 2017, 9721362	2	6
66	Concepts and Strategies in Retinal Gene Therapy. **2017**, 58, 5399-5411		16
65	Development of a Chromatic Pupillography Protocol for the First Gene Therapy Trial in Patients With CNGA3-Linked Achromatopsia. **2017**, 58, 1274-1282		20
64	A Quantitative and Qualitative Exploration of Photoaversion in Achromatopsia. **2017**, 58, 3537-3546		14
63	Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. *Ophthalmic Genetics*, **2018**, 39, 149-157	1.2	59
62	Gene therapy for inherited retinal and optic nerve degenerations. *Expert Opinion on Biological Therapy*, **2018**, 18, 37-49	5.4	55
61	Otx2-Genetically Modified Retinal Pigment Epithelial Cells Rescue Photoreceptors after Transplantation. *Molecular Therapy*, **2018**, 26, 219-237	11.7	15
60	Retinal Gene Therapy. *Methods in Molecular Biology*, **2018**,	1.4	5
59	Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa. *Methods in Molecular Biology*, **2018**, 1715, 33-46	1.4	3
58	Advanced Ocular Injection Techniques for Therapy Approaches. *Methods in Molecular Biology*, **2018**, 1715, 215-223	1.4	1
57	A Novel Achromatopsia Mouse Model Resulting From a Naturally Occurring Missense Change in Cngb3. **2018**, 59, 6102-6110		3
56	Clinical applications of retinal gene therapies. *Precision Clinical Medicine*, **2018**, 1, 5-20	6.7	9
55	Development of optokinetic tracking software for objective evaluation of visual function in rodents. *Scientific Reports*, **2018**, 8, 10009	4.9	5
54	Blinded by the light: a nonhuman primate model of achromatopsia. *Journal of Clinical Investigation*, **2019**, 129, 513-515	15.9	2
53	Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye. *Pharmaceutical Research*, **2018**, 36, 29	4.5	88
52	Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. *Clinical and Experimental Ophthalmology*, **2019**, 47, 521-536	2.4	24
51	Gene therapy in animal models. **2020**, 297-311		

50	Generation of Nonhuman Primate Model of Cone Dysfunction through AAV-Mediated Ablation. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 869-879	6.4	8
49	Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration. *BioDrugs*, **2020**, 34, 763-781	7.9	11
48	Evaluation of Photoreceptor Transduction Efficacy of Capsid-Modified Adeno-Associated Viral Vectors Following Intravitreal and Subretinal Delivery in Sheep. *Human Gene Therapy*, **2020**, 31, 719-729	4.8	7
47	Ophthalmic Wearable Devices for Color Blindness Management. *Advanced Materials Technologies*, **2020**, 5, 1901134	6.8	13
46	Photoreceptor Structure in GNAT2-Associated Achromatopsia. **2020**, 61, 40		19
45	Diminished Cone Sensitivity in cpfl3 Mice Is Caused by Defective Transducin Signaling. **2020**, 61, 26		0
44	Contact Lenses for Color Vision Deficiency. *Advanced Materials Technologies*, **2021**, 6, 2000797	6.8	10
43	Color vision. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2021**, 178, 131-153	3	3
42	Ocular Gene Therapies. **2021**, 1-28		
41	Novel therapeutics in nystagmus: what has the genetics taught us so far?. *Therapeutic Advances in Rare Disease*, **2021**, 2, 263300402199871	1.4	1
40	Progressive and Stationary Disorders of Cone Function: Cone and Cone-Rod Dystrophies and Cone Dysfunction Syndromes. **2021**, 1-29		
39	Gene therapy in color vision deficiency: a review. *International Ophthalmology*, **2021**, 41, 1917-1927	2.2	5
38	Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. *Clinical and Experimental Ophthalmology*, **2021**, 49, 270-288	2.4	12
37	Light-mediated planar polarization of cone photoreceptor cilia contributes to visual acuity in mammals.		1
36	Achromatopsia as a potential candidate for gene therapy. *Advances in Experimental Medicine and Biology*, **2010**, 664, 639-46	3.6	29
35	Adeno-associated virus serotype-9 mediated retinal outer plexiform layer transduction is mainly through the photoreceptors. *Advances in Experimental Medicine and Biology*, **2010**, 664, 671-8	3.6	8
34	Mouse models for cone degeneration. *Advances in Experimental Medicine and Biology*, **2014**, 801, 567-73	3.6	7
33	Cone specific promoter for use in gene therapy of retinal degenerative diseases. *Advances in Experimental Medicine and Biology*, **2014**, 801, 695-701	3.6	12

32	Optimized technique for subretinal injections in mice. *Methods in Molecular Biology*, **2013**, 935, 343-9	1.4	23
31	AAV Vector-Based Gene Therapy, Progress and Current Challenges. **2017**, 77-112		2
30	A demonstration of cone function plasticity after gene therapy in achromatopsia.		2
29	Gene therapy and genome surgery in the retina. *Journal of Clinical Investigation*, **2018**, 128, 2177-2188	15.9	76
28	A nonhuman primate model of inherited retinal disease. *Journal of Clinical Investigation*, **2019**, 129, 863-874	15.9	46
27	Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. *PLoS ONE*, **2009**, 4, e7410	3.7	54
26	Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. *PLoS ONE*, **2010**, 5, e11306	3.7	79
25	AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. *PLoS ONE*, **2012**, 7, e35250	3.7	91
24	Comparative analysis of gene transfer to human and rat retinal pigment epithelium cell line by a combinatorial use of recombinant adeno- associated virus and ultrasound or/and microbubbles. *Bosnian Journal of Basic Medical Sciences*, **2009**, 9, 174-81	3.3	7
23	AAV-mediated human CNGB3 restores cone function in an all-cone mouse model of achromatopsia. *Journal of Biomedical Research*, **2019**, 34, 114-121	1.5	1
22	Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art. *Frontiers in Medicine*, **2021**, 8, 750586	4.9	3
21	Loss of visual and retinal function in light-stressed mice. *Advances in Experimental Medicine and Biology*, **2008**, 613, 157-64	3.6	
20	Gene-Based Medicines Targeting Genetic Defects Directly and Molecular Pathologies Common to Multiple Forms of Disease. *SpringerBriefs in Genetics*, **2012**, 11-30		
19	30 Years Later. **2019**,		2
18	Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. *Molecular Vision*, **2008**, 14, 1760-9	2.3	128
17	Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. *Molecular Vision*, **2009**, 15, 267-75	2.3	37
16	Adeno-associated virus serotype-9 efficiently transduces the retinal outer plexiform layer. *Molecular Vision*, **2009**, 15, 1374-82	2.3	19
15	Nonviral ocular gene therapy: assessment and future directions. *Current Opinion in Molecular Therapeutics*, **2008**, 10, 456-63		27

14	Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. *Molecular Vision*, **2011**, 17, 1090-102	2.3	28
13	Gene therapy in animal models of autosomal dominant retinitis pigmentosa. *Molecular Vision*, **2012**, 18, 2479-96	2.3	43
12	Gene Therapy for Color Blindness. *Yale Journal of Biology and Medicine*, **2017**, 90, 543-551	2.4	14
11	Achromatopsia: Genetics and Gene Therapy. *Molecular Diagnosis and Therapy*, **2021**, 1	4.5	2
10	Two-dimensional biocompatible plasmonic contact lenses for color blindness correction.. *Scientific Reports*, **2022**, 12, 2037	4.9	3
9	Manufacturing Considerations and Challenges for AAV Ocular Gene Therapy. *AAPS Advances in the Pharmaceutical Sciences Series*, **2021**, 613-633	0.5	
8	Gene Therapy in Opn1mw-/-/Opn1sw-/- Mice and Implications for Blue Cone Monochromacy Patients with Deletion Mutations.. *Human Gene Therapy*, **2022**,	4.8	1
7	Progressive and Stationary Disorders of Cone Function: Cone and Cone-Rod Dystrophies and Cone Dysfunction Syndromes. **2022**, 3937-3965		
6	Ocular Gene Therapies. **2022**, 2883-2910		
5	Optogenetic approaches to gene therapy for vision restoration in retinal degenerative diseases. **2022**, 581-606		0
4	Post-developmental plasticity of the primary rod pathway allows restoration of visually guided behaviors. **2022**,		1
3	Gene Therapy Cargos Based on Viral Vector Delivery. **2022**, 22,		1
2	Plasmonic Eyeglasses Based on Gold Nanoparticles for Color Vision Deficiency Management. **2022**, 5, 18788-18798		0
1	Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. **2023**, 15, 698		0